Quantification of designer nuclease induced mutation rates: a direct comparison of different methods

Por Eric Ehrke-Schulz, Thorsten Bergmann, Maren Schiwon, Johannes Doerner, Kamola Saydaminova, Andre Lieber, Anja Ehrhardt
Publicado em 2016-01-01

Immuno-therapy with anti-CTLA4 antibodies in tolerized and non-tolerized mouse tumor models.

Por Jonas Persson, Ines Beyer, Roma Yumul, ZongYi Li, Hans-Peter Kiem, Steve Roffler, André Lieber
Publicado em 2011-01-01

Binding Mechanism Elucidation of the Acute Respiratory Disease Causing Agent Adenovirus of Serotype 7 to Desmoglein-2

Por Marc-André Hograindleur, Gregory Effantin, Daphna Fenel, Caroline Mas, André Lieber, Guy Schoehn, Pascal Fender, Emilie Vassal-Stermann
Publicado em 2020-09-01

Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy

Por Sadia Zafar, Suvi Parviainen, Mikko Siurala, Otto Hemminki, Riikka Havunen, Siri Tähtinen, Simona Bramante, Lotta Vassilev, Hongjie Wang, Andre Lieber, Silvio Hemmi, Tanja de Gruijl, Anna Kanerva, Akseli Hemminki
Publicado em 2017-02-01

Translational development of a tumor junction opening technology

Por Jiho Kim, Chang Li, Hongjie Wang, Swarnendu Kaviraj, Sanjay Singh, Laxman Savergave, Arjun Raghuwanshi, Sucheol Gil, Audrey Germond, Audrey Baldessari, Bingmae Chen, Steve Roffler, Pascal Fender, Charles Drescher, Darrick Carter, André Lieber
Publicado em 2022-05-01